Cover Image
Market Research Report

Gamma Secretase - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 363575
Published Content info 77 Pages
Delivery time: 1-2 business days
Price
Back to Top
Gamma Secretase - Pipeline Review, H1 2020
Published: April 30, 2020 Content info: 77 Pages
Description

Summary:

According to the recently published report 'Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The report 'Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular and Metabolic Disorders which include indications Alzheimer's Disease, Adenoid Cystic Carcinoma (ACC), Benign Tumor, Hearing Disorders, Metastatic Breast Cancer, Soft Tissue Sarcoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Acute Sensorineural Hearing Loss, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Leiomyosarcoma, Leukemia, Lymphoblastic Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Natural Killer Cell Lymphomas, Obesity, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor, T-Cell Leukemia, T-Cell Lymphomas and Triple-Negative Breast Cancer (TNBC).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
  • The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2395TDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gamma Secretase (EC 3.4.23.) - Overview
  • Gamma Secretase (EC 3.4.23.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
  • Adipo Therapeutics LLC
  • AlzeCure Pharma AB
  • Astellas Pharma Inc
  • Audion Therapeutics BV
  • Ayala Pharmaceuticals Inc
  • Eli Lilly and Co
  • Everfront Biotech Inc
  • Lipopharma Therapeutics SL
  • Merck & Co Inc
  • NeuroGenetic Pharmaceuticals Inc
  • Pharchoice Therapeutics Inc
  • Pipeline Therapeutics Inc
  • SpringWorks Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Gamma Secretase (EC 3.4.23.) - Drug Profiles
  • ACD-679 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACD-680 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AL-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AL-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • crenigacestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dibenzazepine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EF-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSI-34 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LP-226A1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3056480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NGP-555 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nirogacestat hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PIPE-505 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gamma Secretase (EC 3.4.23.) - Dormant Products
  • Gamma Secretase (EC 3.4.23.) - Discontinued Products
  • Gamma Secretase (EC 3.4.23.) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039
  • Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
  • Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline's BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
  • Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
  • Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
  • Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
  • Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
  • May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
  • May 20, 2019: SpringWorks Therapeutics announces initiation of Phase 3 trial (DeFi) of nirogacestat in adult patients with desmoid tumors
  • May 13, 2019: FDA grants Orphan Drug Designation to Ayala's AL101 for potential treatment of adenoid cystic carcinoma (ACC)
  • Mar 07, 2019: New drug could restore hearing in the deaf
  • Mar 06, 2019: Ayala Pharmaceuticals to present preclinical data at AACR for AL101, a pan-notch inhibitor being evaluated for adenoid cystic carcinoma
  • Feb 05, 2019: Audion Therapeutics and REGAIN consortium announce positive phase I results in patients with sensorineural hearing loss
  • Dec 17, 2018: Ayala Pharmaceuticals announces first patient enrolled in phase 2 study of lead product candidate AL101 for Adenoid Cystic Carcinoma with notch activated mutations
  • Nov 07, 2018: SpringWorks Therapeutics receives FDA fast track designation for Nirogacestat for the treatment of adult patients with desmoid tumors
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Adipo Therapeutics LLC, H1 2020
  • Pipeline by AlzeCure Pharma AB, H1 2020
  • Pipeline by Astellas Pharma Inc, H1 2020
  • Pipeline by Audion Therapeutics BV, H1 2020
  • Pipeline by Ayala Pharmaceuticals Inc, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by Everfront Biotech Inc, H1 2020
  • Pipeline by Lipopharma Therapeutics SL, H1 2020
  • Pipeline by Merck & Co Inc, H1 2020
  • Pipeline by NeuroGenetic Pharmaceuticals Inc, H1 2020
  • Pipeline by Pharchoice Therapeutics Inc, H1 2020
  • Pipeline by Pipeline Therapeutics Inc, H1 2020
  • Pipeline by SpringWorks Therapeutics Inc, H1 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top